Cerebrospinal Fluid Biomarkers and Memory Present Distinct Associations along the Continuum from Healthy Subjects to AD Patients

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Journal of Alzheimer's Disease

• Publication date

  2011-02-26

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.3233/JAD-2010-101422PMID 21098971
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Feed‐forward hierarchical model of the ventral visual stream applied to functional brain image classification

  2014cited by this paper
• Escala de inteligencia de Wechsler para adultos-IV (WAIS-IV)

  2013cited by this paper
• Memory in individuals with mild cognitive impairment in relation to APOE and CSF Aβ42

  2010cited by this paper
• Relationship between atrophy and β‐amyloid deposition in Alzheimer disease

  2010cited by this paper
• Correlation of longitudinal cerebrospinal fluid biomarkers with cognitive decline in healthy older adults.

  2010cited by this paper
• Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade.

  2010cited by this paper
• Effect of apolipoprotein E on biomarkers of amyloid load and neuronal pathology in Alzheimer disease

  2009cited by this paper
• Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects

  2009cited by this paper
• Cerebrospinal fluid biomarkers and rate of cognitive decline in very mild dementia of the Alzheimer type.

  2009cited by this paper
• Increased Total TAU But Not Amyloid-β42; in Cerebrospinal Fluid Correlates with Short-Term Memory Impairment in Alzheimer's Disease

  2009influential reference
• Decreased cerebrospinal fluid Aβ42 correlates with brain atrophy in cognitively normal elderly

  2009cited by this paper
• False Recognition Correlates with Amyloid-β1–42 but not with Total Tau in Cerebrospinal Fluid of Patients with Dementia and Mild Cognitive Impairment

  2009cited by this paper
• Episodic memory and speed/attention deficits are associated with Alzheimer-typical CSF abnormalities in MCI

  2008cited by this paper
• The Alzheimer's disease neuroimaging initiative (ADNI): MRI methods

  2008cited by this paper
• Normative data for the Boston Naming Test and the Pyramids and Palm Trees Test in the elderly Spanish population

  2008cited by this paper
• Biochemical markers in persons with preclinical familial Alzheimer disease

  2008cited by this paper
• [Standard values of frontal cognitive functioning tests for those over 60 years of age].

  2007cited by this paper
• Cerebrospinal Fluid Biomarkers Predict Decline in Subjective Cognitive Function over 3 Years in Healthy Elderly

  2007cited by this paper
• Valores normativos de tests de función cognitiva frontal para la población mayor de 60 años

  2007cited by this paper
• Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria.

  2007cited by this paper
• [Perception Digital Test (PDT) for the assessment of incipient visual disorder in initial Alzheimer's disease].

  2007cited by this paper
• Test Digital de Percepción (TDP) para la valoración de trastornos perceptivos incipientes en la enfermedad de Alzheimer inicial

  2007cited by this paper
• Total tau protein, phosphorylated tau (181p) protein, beta-amyloid(1-42), and beta-amyloid(1-40) in cerebrospinal fluid of patients with dementia with Lewy bodies.

  2006cited by this paper
• Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study.

  2006cited by this paper
• CSF Biomarkers for Alzheimer’s Disease: Levels of β-Amyloid, Tau, Phosphorylated Tau Relate to Clinical Symptoms and Survival

  2006cited by this paper
• Total tau protein, phosphorylated tau (181p) protein, β-amyloid1–42, and β-amyloid1–40 in cerebrospinal fluid of patients with dementia with Lewy bodies

  2006cited by this paper
• Biomarker profiles and their relation to clinical variables in mild cognitive impairment

  2005cited by this paper
• Familial Alzheimer disease: Decreases in CSF Aβ42 levels precede cognitive decline

  2005cited by this paper
• The 9 year cognitive decline before dementia of the Alzheimer type: a prospective population-based study.

  2005cited by this paper
• Cerebrospinal fluid TAU protein and amyloid β42 in mild cognitive impairment: prediction of progression to Alzheimer’s disease and correlation with the neuropsychological examination

  2005cited by this paper
• CSF biomarkers for mild cognitive impairment and early Alzheimer's disease.

  2005cited by this paper
• Amyloid β(1–42) and phosphorylated tau in CSF as markers for early-onset Alzheimer disease

  2004cited by this paper
• Amyloid beta(1-42) and phosphorylated tau in CSF as markers for early-onset Alzheimer disease.

  2004cited by this paper
• Advances in the early detection of Alzheimer's disease

  2004cited by this paper
• Early Aβ accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain

  2004cited by this paper
• Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease.

  2003cited by this paper
• Neurofibrillary tangles, amyloid, and memory in aging and mild cognitive impairment.

  2003cited by this paper
• Decreased (cid:1) -Amyloid 1-42 and Increased Tau Levels in Cerebrospinal Fluid of Patients With Alzheimer Disease

  2003cited by this paper
• Parahippocampal tau pathology in healthy aging, mild cognitive impairment, and early Alzheimer's disease

  2002cited by this paper
• Current concepts in mild cognitive impairment.

  2001cited by this paper
• WAIS-III: Escala de Inteligencia de Wechsler para Adultos III. Manual técnico

  1999cited by this paper
• The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part I. Clinical and neuropsychological assesment of Alzheimer's disease

  1989cited by this paper
• Genuine memory deficits in dementia

  1987cited by this paper
• Measurement of functional activities in older adults in the community.

  1982cited by this paper
• “Mini-mental state”: A practical method for grading the cognitive state of patients for the clinician

  1975cited by this paper
• Word fluency and brain damage

  1967cited by this paper
• Validity of the Trail Making Test as an Indicator of Organic Brain Damage

  1958cited by this paper

• Disclosure of Alzheimer’s disease blood-based biomarker results in a primary care setting: Opportunities and challenges

  2025cites this paper
• Clusters of cognitive performance predict long‐term cognitive impairment in elderly patients with subjective memory complaints and healthy controls

  2024cites this paper
• Employing Verbal Divergent Thinking to Mitigate Cognitive Decline: Current State of Research and Reasons to Support Its Use

  2024cites this paper
• Predictive value for cerebrospinal fluid Alzheimer's disease profile of different measures of verbal episodic memory in patients with MCI

  2024cites this paper
• An attention-based deep learning approach for the classification of subjective cognitive decline and mild cognitive impairment using resting-state EEG

  2023cites this paper
• Tracking the progression of Alzheimer's disease: Insights from metabolic patterns of SOMI stages.

  2023cites this paper
• Diagnostic Accuracy of the Five-Word Test for Mild Cognitive Impairment Due to Alzheimer’s Disease

  2022cites this paper
• Cholinergic white matter pathways along the Alzheimer's disease continuum

  2022cites this paper
• Decreased Cortical Thickness and Local Gyrification in Individuals with Subjective Cognitive Impairment

  2021cites this paper
• Association of Subjective Cognitive Decline with Cerebrospinal Fluid Biomarkers of Alzheimer’s Disease Pathology in Cognitively Intact Older Adults: The CABLE Study

  2021cites this paper
• Look who is complaining: Psychological factors predicting subjective cognitive complaints in a large community sample of older adults

  2021cites this paper
• Cerebrospinal fluid neurofilament light predicts the rate of executive function decline in younger-onset dementia.

  2021cites this paper
• Optimal Combinations of AT(N) Biomarkers to Determine Longitudinal Cognition in the Alzheimer's Disease

  2021cites this paper
• Value of CSF Biomarkers in Predicting Risk of Progression from aMCI to ADD in a 5-Year Follow-Up Cohort

  2020cites this paper
• Abnormal Regional and Global Connectivity Measures in Subjective Cognitive Decline Depending on Cerebral Amyloid Status

  2020cites this paper
• Cross-sectional associations of amyloid burden with semantic cognition in older adults without dementia: A systematic review and meta-analysis

  2020cites this paper
• Relationship Between PET-Assessed Amyloid Burden and Visual and Verbal Episodic Memory Performance in Elderly Subjects

  2020cites this paper
• AD-Related CSF Biomarkers Across Distinct Levels of Cognitive Impairment: Correlations With Global Cognitive State

  2020cites this paper
• Parkinson disease with mild cognitive impairment: Domain‐specific cognitive complaints predict dementia

  2020cites this paper
• Amyloid Plaques and Symptoms of Depression Links to Medical Help-Seeking due to Subjective Cognitive Decline

  2020cites this paper
• Dual-Task Performance and Neurodegeneration: Correlations Between Timed Up-and-Go Dual-Task Test Outcomes and Alzheimer’s Disease Cerebrospinal Fluid Biomarkers

  2019cites this paper
• Subjective cognitive decline and progression to dementia in Parkinson’s disease: a long-term follow-up study

  2019cites this paper
• Prevalence of abnormal Alzheimer’s disease biomarkers in patients with subjective cognitive decline: cross-sectional comparison of three European memory clinic samples

  2019cites this paper
• Cerebrospinal fluids from Alzheimer's disease patients exhibit neurotoxic effects on neuronal cell cultures

  2019cites this paper
• Relevance of the interplay between amyloid and tau for cognitive impairment in early Alzheimer's disease.

  2019cites this paper
• Correlation between CSF biomarkers of Alzheimer’s disease and global cognition in a psychogeriatric clinic cohort

  2019cites this paper
• Biomarker-Based Signature of Alzheimer’s Disease in Pre-MCI Individuals

  2019cites this paper
• Medial temporal lobe white matter pathway variability is associated with individual differences in episodic memory in cognitively normal older adults.

  2019cites this paper
• Subtle Cognitive Impairment and Alzheimer’s Disease-Type Pathological Changes in Cerebrospinal Fluid are Common Among Neurologically Healthy Subjects

  2018cites this paper
• The Dimensional Structure of Subjective Cognitive Decline

  2018cites this paper
• Dynamics of proteinopathies in Alzheimer’s disease as measured by PET and CSF biomarkers

  2018cites this paper
• Age-related hearing loss and neurocognitive function: Normal and pathological processes in cognitive ageing

  2018cites this paper
• CSF Aβ1–42, but not p-Tau181, Predicted Progression from Amnestic MCI to Alzheimer’s Disease Dementia

  2018cites this paper
• Subjective cognitive decline: preclinical manifestation of Alzheimer’s disease

  2018cites this paper
• Memory Correlates of Alzheimer’s Disease Cerebrospinal Fluid Markers: A Longitudinal Cohort Study

  2017cites this paper
• Prediction of Free and Cued Selective Reminding Test Performance Using Volumetric and Amyloid-Based Biomarkers of Alzheimer’s Disease

  2016cites this paper
• Revista Española de Geriatría y Gerontología

  2016cites this paper
• Verbal Memory and Visual Perception in early Alzheimer’s disease: Contribution of new diagnostic tools for new classification criteria

  2016cites this paper
• Low Cerebrospinal Fluid Amyloid-Beta Concentration Is Associated with Poorer Delayed Memory Recall in Women

  2016cites this paper
• Demencia: estados preclínicos y mortalidad en cohortes suecas

  2016cites this paper
• Subjective Memory Impairment and Gait Variability in Cognitively Healthy Individuals: Results from a Cross-Sectional Pilot Study

  2016cites this paper
• Specific Features of Subjective Cognitive Decline Predict Faster Conversion to Mild Cognitive Impairment

  2016cites this paper
• Altered Brain Connectivity in Early Postmenopausal Women with Subjective Cognitive Impairment

  2016cites this paper
• Subjective cognitive impairment: Towards early identification of Alzheimer disease.

  2016cites this paper
• Two-stage screening for early dementia in primary care

  2016cites this paper
• Relationship between cerebrospinal fluid biomarkers of Alzheimer's disease and cognition in cognitively normal older adults.

  2015cites this paper
• Free and Cued Selective Reminding Test is superior to the Wechsler Memory Scale in discriminating mild cognitive impairment from Alzheimer's disease

  2015cites this paper
• Biochemical and Neuroimaging Studies in Subjective Cognitive Decline: Progress and Perspectives

  2015cites this paper
• Evolving Evidence for the Value of Neuroimaging Methods and Biological Markers in Subjects Categorized with Subjective Cognitive Decline

  2015cites this paper
• Comparison of “Word” vs. “Picture” version of the Free and Cued Selective Reminding Test (FCSRT) in older adults

  2015cites this paper
• Amyloid and Tau Biomarkers in Subjective Cognitive Impairment

  2015cites this paper
• Cortical Thinning in Individuals with Subjective Memory Impairment

  2015cites this paper
• Subjective cognitive decline is related to CSF biomarkers of AD in patients with MCI

  2015cites this paper
• Influence of Sampling and Recruitment Methods in Studies of Subjective Cognitive Decline

  2015cites this paper
• The Alzheimer's disease mitochondrial cascade hypothesis: progress and perspectives.

  2014cites this paper
• Screening Older Latinos for Dementia in the Primary Care Setting

  2014cites this paper
• Mild Cognitive Impairment: Diagnosis, Longitudinal Course, and Emerging Treatments

  2014cites this paper
• The free and cued selective reminding test distinguishes frontotemporal dementia from Alzheimer's disease.

  2014cites this paper
• A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease

  2014cites this paper
• Subjective Cognitive Impairment Subjects in Our Clinical Practice

  2014cites this paper
• Meta-Review of CSF Core Biomarkers in Alzheimer’s Disease: The State-of-the-Art after the New Revised Diagnostic Criteria

  2014cites this paper
• Preclinical AD predicts decline in memory and executive functions in subjective complaints

  2013cites this paper
• Rapid improvement of canine cognitive dysfunction with immunotherapy designed for Alzheimer's disease.

  2013cites this paper
• The case for soluble Aβ oligomers as a drug target in Alzheimer's disease.

  2013cites this paper
• The AD-CSF-Index Discriminates Alzheimer's Disease Patients from Healthy Controls: A Validation Study

  2013cites this paper
• Distinct Functional Activity of the Precuneus and Posterior Cingulate Cortex During Encoding in the Preclinical Stage of Alzheimer's Disease

  2012cites this paper
• Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: A consensus paper from the Alzheimer's Biomarkers Standardization Initiative

  2012cites this paper
• IC‐02‐04: Ordering of Alzheimer's disease biomarkers

  2011cites this paper
• Brain aging, Alzheimer's disease, and mitochondria.

  2011cites this paper
• [Role of biomarkers in the early diagnosis of Alzheimer's disease].

  2011cites this paper
• Cognitively preserved subjects with transitional cerebrospinal fluid ß-amyloid 1-42 values have thicker cortex in Alzheimer's disease vulnerable areas.

  2011cites this paper
• Identifying Earlier Alzheimer’s Disease: Insights from the Preclinical and Prodromal Phases

  2011cites this paper
• Can we improve care for patients with dementia?

  2011cites this paper